{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-100","upperLimit":"144","value":"-43.3"},{"groupId":"OG001","lowerLimit":"-100","upperLimit":"23","value":"-21.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"Depth of response (or tumour shrinkage or change in tumour size) was assessed using BICR responses in target lesions. The best change in tumour size is the largest decrease from baseline or the smallest increase from baseline in the absence of a reduction","dispersionType":"Full Range","groups":[{"description":"80mg once daily tablet","id":"OG000","title":"Osimertinib"},{"description":"Matching Placebo","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months","title":"Tumour Shrinkage by Blinded Independent Central Review (BICR)","type":"SECONDARY","unitOfMeasure":"% change from baseline"}